Dr James Field

James is accelerating the discovery of next-generation therapeutic antibodies for the treatment of diseases like cancer, by combining the very best of human ingenuity, artificial intelligence (AI) and robotics. A leader in AI-enabled drug discovery, James is unlocking the next wave of major scientific breakthroughs. He regularly speaks at world events and plays a prominent role in briefing policymakers. As CEO and founder of Labgenius, James is pioneering the development of a smart robotic platform capable of designing, conducting and, critically, learning from its own experiments. He has secured >$30M in financing from top-tier venture capital firms, developed a cutting-edge, machine learning-driven protein engineering platform and inked R&D deals with top biotech and pharma companies. Passionate about supporting other deep tech founders, James has backed scientific founders such as Leo Wossnig at Rakho, Nick Kral at Phytoform Labs and Max Jamilly at Hoxton Farms. James now manages European deep tech investments for a US Family Office. A fellow of the prestigious Synthetic Biology Leadership Excellence Accelerator Program (LEAP), James was featured on the Forbes 30 Under 30 list for Science & Healthcare in 2018 and was awarded the BBSRC Innovator of the Year award for early career impact in 2017.